Cargando…

Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With Missense AIP Mutations

CONTEXT: The pathogenic effect of mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene (AIPmuts) in pituitary adenomas is incompletely understood. We have identified the primary mechanism of loss of function for missense AIPmuts. OBJECTIVE: This study sought to analyze the mecha...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernández-Ramírez, Laura C., Martucci, Federico, Morgan, Rhodri M. L., Trivellin, Giampaolo, Tilley, Daniel, Ramos-Guajardo, Nancy, Iacovazzo, Donato, D'Acquisto, Fulvio, Prodromou, Chrisostomos, Korbonits, Márta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971335/
https://www.ncbi.nlm.nih.gov/pubmed/27253664
http://dx.doi.org/10.1210/jc.2016-1307
_version_ 1782446092844007424
author Hernández-Ramírez, Laura C.
Martucci, Federico
Morgan, Rhodri M. L.
Trivellin, Giampaolo
Tilley, Daniel
Ramos-Guajardo, Nancy
Iacovazzo, Donato
D'Acquisto, Fulvio
Prodromou, Chrisostomos
Korbonits, Márta
author_facet Hernández-Ramírez, Laura C.
Martucci, Federico
Morgan, Rhodri M. L.
Trivellin, Giampaolo
Tilley, Daniel
Ramos-Guajardo, Nancy
Iacovazzo, Donato
D'Acquisto, Fulvio
Prodromou, Chrisostomos
Korbonits, Márta
author_sort Hernández-Ramírez, Laura C.
collection PubMed
description CONTEXT: The pathogenic effect of mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene (AIPmuts) in pituitary adenomas is incompletely understood. We have identified the primary mechanism of loss of function for missense AIPmuts. OBJECTIVE: This study sought to analyze the mechanism/speed of protein turnover of wild-type and missense AIP variants, correlating protein half-life with clinical parameters. DESIGN AND SETTING: Half-life and protein–protein interaction experiments and cross-sectional analysis of AIPmut positive patients' data were performed in a clinical academic research institution. PATIENTS: Data were obtained from our cohort of pituitary adenoma patients and literature-reported cases. INTERVENTIONS: Protein turnover of endogenous AIP in two cell lines and fifteen AIP variants overexpressed in HEK293 cells was analyzed via cycloheximide chase and proteasome inhibition. Glutathione-S-transferase pull-down and quantitative mass spectrometry identified proteins involved in AIP degradation; results were confirmed by coimmunoprecipitation and gene knockdown. Relevant clinical data was collected. MAIN OUTCOME MEASURES: Half-life of wild-type and mutant AIP proteins and its correlation with clinical parameters. RESULTS: Endogenous AIP half-life was similar in HEK293 and lymphoblastoid cells (43.5 and 32.7 h). AIP variants were divided into stable proteins (median, 77.7 h; interquartile range [IQR], 60.7–92.9 h), and those with short (median, 27 h; IQR, 21.6–28.7 h) or very short (median, 7.7 h; IQR, 5.6–10.5 h) half-life; proteasomal inhibition rescued the rapid degradation of mutant proteins. The experimental half-life significantly correlated with age at diagnosis of acromegaly/gigantism (r = 0.411; P = .002). The FBXO3-containing SKP1–CUL1–F-box protein complex was identified as the E3 ubiquitin-ligase recognizing AIP. CONCLUSIONS: AIP is a stable protein, driven to ubiquitination by the SKP1–CUL1–F-box protein complex. Enhanced proteasomal degradation is a novel pathogenic mechanism for AIPmuts, with direct implications for the phenotype.
format Online
Article
Text
id pubmed-4971335
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-49713352016-08-17 Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With Missense AIP Mutations Hernández-Ramírez, Laura C. Martucci, Federico Morgan, Rhodri M. L. Trivellin, Giampaolo Tilley, Daniel Ramos-Guajardo, Nancy Iacovazzo, Donato D'Acquisto, Fulvio Prodromou, Chrisostomos Korbonits, Márta J Clin Endocrinol Metab Original Articles CONTEXT: The pathogenic effect of mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene (AIPmuts) in pituitary adenomas is incompletely understood. We have identified the primary mechanism of loss of function for missense AIPmuts. OBJECTIVE: This study sought to analyze the mechanism/speed of protein turnover of wild-type and missense AIP variants, correlating protein half-life with clinical parameters. DESIGN AND SETTING: Half-life and protein–protein interaction experiments and cross-sectional analysis of AIPmut positive patients' data were performed in a clinical academic research institution. PATIENTS: Data were obtained from our cohort of pituitary adenoma patients and literature-reported cases. INTERVENTIONS: Protein turnover of endogenous AIP in two cell lines and fifteen AIP variants overexpressed in HEK293 cells was analyzed via cycloheximide chase and proteasome inhibition. Glutathione-S-transferase pull-down and quantitative mass spectrometry identified proteins involved in AIP degradation; results were confirmed by coimmunoprecipitation and gene knockdown. Relevant clinical data was collected. MAIN OUTCOME MEASURES: Half-life of wild-type and mutant AIP proteins and its correlation with clinical parameters. RESULTS: Endogenous AIP half-life was similar in HEK293 and lymphoblastoid cells (43.5 and 32.7 h). AIP variants were divided into stable proteins (median, 77.7 h; interquartile range [IQR], 60.7–92.9 h), and those with short (median, 27 h; IQR, 21.6–28.7 h) or very short (median, 7.7 h; IQR, 5.6–10.5 h) half-life; proteasomal inhibition rescued the rapid degradation of mutant proteins. The experimental half-life significantly correlated with age at diagnosis of acromegaly/gigantism (r = 0.411; P = .002). The FBXO3-containing SKP1–CUL1–F-box protein complex was identified as the E3 ubiquitin-ligase recognizing AIP. CONCLUSIONS: AIP is a stable protein, driven to ubiquitination by the SKP1–CUL1–F-box protein complex. Enhanced proteasomal degradation is a novel pathogenic mechanism for AIPmuts, with direct implications for the phenotype. Endocrine Society 2016-08 2016-06-02 /pmc/articles/PMC4971335/ /pubmed/27253664 http://dx.doi.org/10.1210/jc.2016-1307 Text en https://creativecommons.org/licenses/by/4.0/ This article has been published under the terms of the Creative Commons Attribution License (CC-BY; https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Copyright for this article is retained by the author(s).
spellingShingle Original Articles
Hernández-Ramírez, Laura C.
Martucci, Federico
Morgan, Rhodri M. L.
Trivellin, Giampaolo
Tilley, Daniel
Ramos-Guajardo, Nancy
Iacovazzo, Donato
D'Acquisto, Fulvio
Prodromou, Chrisostomos
Korbonits, Márta
Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With Missense AIP Mutations
title Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With Missense AIP Mutations
title_full Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With Missense AIP Mutations
title_fullStr Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With Missense AIP Mutations
title_full_unstemmed Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With Missense AIP Mutations
title_short Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With Missense AIP Mutations
title_sort rapid proteasomal degradation of mutant proteins is the primary mechanism leading to tumorigenesis in patients with missense aip mutations
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971335/
https://www.ncbi.nlm.nih.gov/pubmed/27253664
http://dx.doi.org/10.1210/jc.2016-1307
work_keys_str_mv AT hernandezramirezlaurac rapidproteasomaldegradationofmutantproteinsistheprimarymechanismleadingtotumorigenesisinpatientswithmissenseaipmutations
AT martuccifederico rapidproteasomaldegradationofmutantproteinsistheprimarymechanismleadingtotumorigenesisinpatientswithmissenseaipmutations
AT morganrhodriml rapidproteasomaldegradationofmutantproteinsistheprimarymechanismleadingtotumorigenesisinpatientswithmissenseaipmutations
AT trivellingiampaolo rapidproteasomaldegradationofmutantproteinsistheprimarymechanismleadingtotumorigenesisinpatientswithmissenseaipmutations
AT tilleydaniel rapidproteasomaldegradationofmutantproteinsistheprimarymechanismleadingtotumorigenesisinpatientswithmissenseaipmutations
AT ramosguajardonancy rapidproteasomaldegradationofmutantproteinsistheprimarymechanismleadingtotumorigenesisinpatientswithmissenseaipmutations
AT iacovazzodonato rapidproteasomaldegradationofmutantproteinsistheprimarymechanismleadingtotumorigenesisinpatientswithmissenseaipmutations
AT dacquistofulvio rapidproteasomaldegradationofmutantproteinsistheprimarymechanismleadingtotumorigenesisinpatientswithmissenseaipmutations
AT prodromouchrisostomos rapidproteasomaldegradationofmutantproteinsistheprimarymechanismleadingtotumorigenesisinpatientswithmissenseaipmutations
AT korbonitsmarta rapidproteasomaldegradationofmutantproteinsistheprimarymechanismleadingtotumorigenesisinpatientswithmissenseaipmutations